Immunohistology of the Breast

Diagnostic Immunohistochemistry, Second Edition

Volumn , Issue , 2006, Pages 699-745

  Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749480737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06652-8.50023-5     Document Type: Chapter

References (376)

1. MG Joshi, AKC Lee, CA Pederson, et al. (1996) The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. Mod Pathol 9 57-62.
2. PS Rudland, SJ Leinster, J Winstanley, et al. (1993) Immunocytochemical identification of cell types in benign and malignant breast diseases: Variations in cell markers accompany the malignant state. J Histochem Cytochem 41 543-553.
3. B Gusterson, MJ Warburton, D Mitchell, et al. (1982) Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res 42 4763-4770.
4. G Bussolati, G Botta and P Gugliotta (1980) Actin-rich (myoepithelial cells) in ductal carcinoma in situ of the breast. Virchows Arch B 34 251-259.
5. G Bussolati (1980) Actin-rich (myoepithelial) cells in lobular carcinoma in situ of the breast. Virchows Arch B 32 165-176.
6. G Bussolati, FB Botto-Micca, V Eusebi, et al. (1981) Myoepithelial cells in lobular carcinoma in situ of the breast. Ultrastruct Pathol 2 219-230.
7. A Ahmed (1974) The myoepithelium in human breast carcinoma. J Pathol 113 129-135.
8. VE Gould, W Jao and H Battifora (1980) Ultrastructural analysis in the differential diagnosis of breast tumors: The significance of myoepithelial cells, basal lamina, intracytoplasmic lumina and secretory granules. Pathol Res Pract 167 45-70.
9. YM Hijazi, JL Lessard, MA Weiss, et al. (1989) Use of anti-actin and S-100 protein antibodies in differentiating benign and malignant sclerosing breast lesions. Surg Pathol 2 125-135.
10. S Dwarakanath, AK Lee, RA Dellilis, et al. (1987) S-100 protein positivity in breast carcinomas: A potential pitfall in diagnostic immunohistochemistry. Hum Pathol 18 1144-1148.
11. U Raju, MW Lee, RJ Zarbo, et al. (1989) Papillary neoplasia of the breast: Immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms. Mod Pathol 2 569-576.
12. R Nagle, W Bocker, JR Davis, et al. (1986) Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34 869-881.
13. E Jarasch, RB Nagle, M Kaufman, et al. (1988) Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 19 276-289.
14. SM Lele, K Graves and Z Gatalica (2000) Immunohistochemical detection of maspin is a useful adjunct in distinguishing radial sclerosing lesion from tubular carcinoma of the breast. Appl Immunohistochem Mol Morphol 8(1), 32-36.
15. SK Mohsin, et al. (2003) Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199(4), 432-435.
16. Y Umekita and H Yoshida (2003) Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 42(6), 541-545.
17. R.L. Navarro R de L, MT Martins and V.C. Araujo VC de (2004) Maspin expression in normal and neoplastic salivary gland. J Oral Pathol Med 33(7), 435-440.
18. G Acs, et al. (2001) Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115(1), 85-98.
19. W Bocker, B Bier, G Freytag, et al. (1992) An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II. Virchows Arch A Pathol Anat Histopathol 421 323-330.
20. C Gottlieb, U Raju and KA Greenwald (1990) Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: An immunohistochemical study. Mod Pathol 3 135-140.
21. P Gugliotta, A Sapino, L Macri, et al. (1993) Specific demonstration of myoepithelial cells by anti-alpha smooth muscle actin antibody. J Histochem Cytochem 36 659-663.
22. WA Raymond and AS Leong (1991) Assessment of invasion in breast lesions using antibodies to basement membrane components and myoepithelial cells. Pathology 23 291-297.
23. S Bose, CM DeRosa and L Ozzello (1999) Immunostaining of type IV collagen and smooth muscle actin as an aid in the diagnosis of breast lesions. Breast J 5 194-201.
24. N Wang, BC Wan, M Skelly, et al. (1997) Antibodies to novel myoepithelium-associated proteins distinguish benign lesions and carcinoma in situ from invasive carcinoma of the breast. Appl Immunohistochem 5 141-151.
25. MA Titus (1993) Myosins. Curr Opin Cell Biol 5 77-81.
26. SJ Winder and MP Walsh (1993) Calponin: Thin filament-linked regulation of smooth muscle contraction. Cell Signal 5 677-686.
27. M Gimoa, M Herzog, J Vancekerckhove, et al. (1990) Smooth muscle specific expression of calponin. FEBS Lett 274 159-162.
28. Dabbs DJ, Pickeral J, Tung MY, et al. Predicting invasion in stereotactic core biopsies of breast: Qualitative differences of antibodies that detect myoepithelial cells. Mod Pathol, in press.
29. A Someren and CW Sewell (1997) Differential diagnosis in pathology: breast disorders New York: Igaku-Shoin
30. RW Werling, et al. (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27(1), 82-90.
31. M Barbareschi, et al. (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25(8), 1054-1060.
32. O Kaufmann, et al. (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116(6), 823-830.
33. X Duan and D Dabbs (2004) Smooth muscle myosin heavy chain and p63 for diagnosis of difficult lesions on core biopsies of the breast. Mod Pathol 17 22A.
34. V Eusebi, MP Foschini, CM Betts, et al. (1993) Microglandular adenosis, apocrine adenosis, and tubular carcinoma of the breast: An immunohistochemical comparison. Am J Surg Pathol 17 99-109.
35. DT Wheeler, et al. (2004) Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol 28(12), 1587-1593.
36. KC Lee, JK Chan and E Gwi (1996) Tubular adenosis of the breast: A distinct benign lesion mimicking invasive carcinoma. Am J Surg Pathol 20 46-54.
37. V Eusebi, G Collina and G Bussolati (1989) Carcinoma in situ in sclerosing adenosis of the breast: An immunohistochemical study. Semin Diagn Pathol 6 146-152.
38. S Rasbridge (1995) Carcinoma in situ involving sclerosing adenosis: A mimic of invasive breast carcinoma. Histopathology 27 269-273.
39. M Papotti, P Gugliotta, V Eusebi, et al. (1983) Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol 7 451-461.
40. C Purcell and HJ Norris (1998) Intraductal proliferations of the breast: A review of histologic criteria for atypical ductal hyperplasia and ductal carcinoma in situ, including apocrine and papillary lesions. Ann Diagn Pathol 2 135-145.
41. CD McKinney and RE Fechner (1995) Papillomas of the breast: A histologic spectrum including atypical hyperplasia and duct carcinoma in situ. Pathol Annu 30 137-178.
42. U Raju and D Vertes (1996) Breast papillomas with atypical ductal hyperplasia. Hum Pathol 27 1231-1238.
43. S Barsky, GP Siegal, F Jannota, et al. (1983) Loss of basement membrane components by invasive tumors but not their benign counterparts. Lab Invest 49 140-147.
44. G Chomette, M Auriol, P Tranbaloc, et al. (1990) Stromal changes in early invasive breast carcinoma: An immunohistochemical, histoenzymological and ultrastructural study. Pathol Res Pract 186 70-79.
45. CB Hill and IT Yeh (2005) Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 123(1), 36-44.
46. R Simpson, N Cope, A Skalova, et al. (1998) Malignant adenomyoepithelioma of the breast with mixed osteogenic, spindle cell and carcinomatous differentiation. Am J Surg Pathol 22 631-636.
47. E Maiorano, R Ricco, D Virgintino, et al. (1994) Infiltrating myoepithelioma of the breast. Appl Immunohistochem 2 130-136.
48. M Foschini and V Eusebi (1998) Carcinomas of the breast showing myoepithelial cell differentiation: A review of the literature. Virchows Arch 432 303-310.
49. PC Chen, CK Chen, AD Nicastri, et al. (1994) Myoepithelial carcinoma of the breast with distant metastasis and accompanied by adenomyoepitheliomas. Histopathology 24 543-548.
50. RH Young (1988) Adenomyoepithelioma of the breast: A report of three cases and review of the literature. Am J Clin Pathol 89 308-314.
51. PS Thorner, HJ Kahn, R Baumal, et al. (1986) Malignant myoepithelioma of the breast: An immunohistochemical study by light and electron microscopy. Cancer Res 57 745-750.
52. F Tavassoli (1991) Myoepithelial lesions of the breast: Myo-epitheliosis, adenomyoepithelioma and myoepithelial carcinoma. Am J Surg Pathol 15 554-568.
53. W Schurch, C Potvin and TA Seemayer (1985) Malignant myoepithelioma (myoepithelial carcinoma) of the breast: An ultrastructural and immunohistochemical study. Ultrastruct Pathol 8 1-11.
54. TA Smith, K Machen, C Fisher, et al. (1999) Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumors. Am J Clin Pathol 112 641-648.
55. H Deligeorgi-Politi, T Kontozoglou, M Joseph, et al. (1997) Myofibroblastoma of the breast: Cytologic, histologic, immunohistochemical and ultrastructural findings in two cases with differing cellularity. Breast J 3 365-371.
56. JL Hornick and CD Fletcher (2004) Cutaneous myoepithelioma: a clinicopathologic and immunohistochemical study of 14 cases. Hum Pathol 35(1), 14-24.
57. JL Hornick and CD Fletcher (2003) Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol 27(9), 1183-1196.
58. MM Koker and CG Kleer (2004) p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 28(11), 1506-1512.
59. M Lacroix-Triki, et al. (2003) Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 442(6), 548-554.
60. M Julien, M Trojani and JM Coindre (1994) Myofibroblastoma of the breast: Report of 8 cases. Ann Pathol 14 143-147.
61. ES Wargotz, SW Weiss and HJ Norris (1987) Myofibroblastoma of the breast: Sixteen cases of a distinctive benign mesenchymal tumor. Am J Surg Pathol 11 493-502.
62. S Damiani, M Miettinin, JL Peterse, et al. (1994) Solitary fibrous tumor (myofibroblastoma) of the breast. Virchows Arch 425 89-92.
63. GF Schwartz, AS Patchefsky, SD Finkelstein, et al. (1989) Nonpalpable in situ ductal carcinoma of the breast: Predictors of multicentricity and microinvasion and implications for treatment. Arch Surg 124 29-32.
64. AS Patchefsky, GF Schwartz, SD Finkelstein, et al. (1989) Heterogeneity of intraductal carcinoma of the breast. Cancer Res 63 731-741.
65. B Dunne, et al. (2003) An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol 34(10), 1009-1015.
66. S Leibl, et al. (2005) Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 29(3), 347-353.
67. NK Popnikolov, et al. (2003) Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Pathol 120(2), 161-167.
68. JS Reis-Filho, et al. (2003) Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 11(1), 1-8.
69. SO Tamimi and A Ahmed (1986) Stromal changes in early invasive and noninvasive breast carcinoma: An ultrastructural study. J Pathol 150 43-49.
70. MJ Silverstein, JR Waisman, P Gamagami, et al. (1990) Intraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice. Cancer 66 102-108.
71. ME Schuh, T Nemoto, RB Penetrante, et al. (1986) Intraductal carcinoma: Analysis of presentation, pathologic findings and outcome of disease. Arch Surg 121 1303-1307.
72. JH Wong, KH Kopald and DL Morton (1990) The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 125 1298-1302.
73. LJ Solin, BL Fowble, I-T Yeh, et al. (1992) Microinvasive ductal carcinoma of the breast treated with breast conserving surgery and definitive radiation. Int J Radiat Oncol Biol Phys 23 961-968.
74. D Rosner, WW Lane and R Penetrante (1991) Duct carcinoma in situ with microinvasion: A curable entity using surgery alone without need for adjuvant therapy. Cancer 67 1498-1503.
75. PW Force (1973) Standardized management of breast cancer specimens. Am J Clin Pathol 60 789-798.
76. PP Rosen (1997) Intraductal carcinoma. Breast pathology Philadelphia: Lippincott-Raven 264-265.
77. ML Prasad, E Hyjek, DD Giri, et al. (1999) Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast. Am J Surg Pathol 23 176-181.
78. S Masood, SJ Sim and L Lu (1992) Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ. Cancer Detect Prev 16 225-235.
79. Y Soini and M Miettinin (1993) Immunohistochemical evaluation of the cytoarchitecture of benign and malignant breast lesions. APMIS 100 901-907.
80. F Monifar, YG Man, RA Lininger, et al. (1999) Use of keratin 34βE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type-benign and malignant intraductal proliferations. Am J Surg Pathol 23 1048-1058.
81. R Ashikari, K Park, A Huvos, et al. (1970) Paget's disease of the breast. Cancer 26 680-685.
82. SJ Kister and CD Haagensen (1977) Paget's disease of the breast. Am J Surg Pathol 119 606-609.
83. D Stefanou, et al. (2004) p63 expression in benign and malignant breast lesions. Histol Histopathol 19(2), 465-471.
84. JT Rabban and MF Lerwill (2005) Cytokeratin 5/6 distinguishes solid papillary ductal carcinoma in situ form florid usual ductal hyperplasia. Mod Pathol 18(Suppl 1), 47A.
85. B Salvadori, G Fariselli and R Saccozzi (1976) Analysis of 100 cases of Paget's disease of the breast. Tumori 62 529-536.
86. K Lundquist, S Kohler and RV Rouse (1999) Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol 23 212-219.
87. Z Zeng, J Melamed, P Symmans, et al. (1999) Benign proliferative nipple duct lesions frequently contain CAM5.2 and anti-cytokeratin 7 immunoreactive cells in the overlying epidermis. Am J Surg Pathol 23 1349-1355.
88. RM Cabanas (1977) An approach for the treatment of penile carcinoma. Cancer 39 456-466.
89. D Reintgen, CW Cruse, K Wells, et al. (1994) The orderly progression of melanoma lymph node metastasis. Ann Surg 220 759-767.
90. E Tani and L Skoog (1988) Immunocytochemical detection of estrogen receptors in mammary Paget cells. Acta Cytol 23 825-828.
91. G Marucci, et al. (2002) Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch 441(2), 117-123.
92. K Meissner, A Riviere, G Haupt, et al. (1990) Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Clin Pathol 137 1305-1309.
93. DX Yao, et al. (2002) Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent inter-epithelial extension of lactiferous duct cells. Histopathology 40(3), 230-236.
94. ME Salama, et al. (2003) p16INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol 149(5), 1006-1012.
95. MM Steinhoff (1999) Axillary node micrometastases: Detection and biologic significance. Breast J 5 325-329.
96. JL Mansi, H Gogas, JM Bliss, et al. (1999) Outcome of primary breast cancer patients with micrometastases: A long-term follow-up study. Lancet 354 197-202.
97. IA Nasser, AK Lee, S Bosari, et al. (1993) Occult axillary lymph node metastases in ‘node negative’ breast carcinoma. Hum Pathol 24 950-957.
98. SS Bass, GH Lyman, CR McCann, et al. (1999) Lymphatic mapping and sentinel lymph node biopsy. Breast J 5 288-295.
99. DJ Dabbs and R Johnson (2004) The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J 10(3), 186-189.
100. K Dowlatshahi, M Fan, KJ Bloom, et al. (1999) Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. Cancer 86 990-996.
101. J Meyer (1998) Sentinel lymph node biopsy: Strategies for pathologic examination of the specimen. J Surg Oncol 69 212-218.
102. SA Roberts, TL Pasha and PJ Zhang (2000) Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma. Arch Pathol Lab Med 124 1310-1313.
103. BJ Czerniecki, AM Scheff, LS Callans, et al. (1999) Immunohistochemistry with pancytokeratins improves sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85 1098-1103.
104. DN Krag, et al. (2004) NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol 11(3 Suppl), 208S-210S.
105. A Chagpar, et al. (2005) Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 241 1005-1012. discussion 1012–1015.
106. C Doglioni, P Dell'Orto, G Zanetti, et al. (1990) Cytokeratin immunoreactive cells of lymph nodes and spleen in normal and pathologic conditions. Virchow's Arch A Pathol Anat Histopathol 416 479-490.
107. P Iuzzolino, L Bontempini, C Doglioni, et al. (1989) Keratin immunoreactivity in extrafollicular reticular cells of the lymph node. Am J Clin Pathol 91 239-240.
108. BA Carter, RA Jensen, JF Simpson, et al. (2000) Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 113 259-265.
109. WH Pearlman, JD Giueriguian, ME Sawyer, et al. (1973) A specific progesterone binding component of human breast fluid. J Biol Chem 248 5736-5741.
110. NM Diaz, et al. (2005) Modes of benign mechanical transport of breast epithelial cells to axillary lymph nodes. Adv Anat Pathol 12(1), 7-9.
111. NM Diaz, et al. (2004) Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am J Surg Pathol 28(12), 1641-1645.
112. NM Diaz, JR Mayes and V Vrcel (2005) Breast epithelial cells in dermal angiolymphatic spaces: A manifestation of benign mechanical transport. Hum Pathol 36(3), 310-313.
113. AS Wong and BM Gumbiner (2003) Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 161(6), 1191-1203.
114. G Berx, et al. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 14(24), 6107-6115.
115. G Acs, TJ Lawton, TR Rebbeck, et al. (2001) Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115 85-98.
116. J Behrens, et al. (1991) The role of E-cadherin and scatter factor in tumor invasion and cell motility. EXS 59 109-126.
117. H Shiozaki, et al. (1991) Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139(1), 17-23.
118. C Gamallo, et al. (1993) Correlation of E-cadherin expression with differentiation of grade and histological type in breast carcinoma. Am J Pathol 142(4), 987-993.
119. N Guriec, et al. (1996) E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invasion Metastasis 16(1), 19-26.
120. S Siitonen, JT Kononen, HJ Helin, et al. (1996) Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105 394-402.
121. C Charpin, et al. (1998) Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 109(4), 431-438.
122. R Yoshida, et al. (2001) The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 18(3), 513-520.
123. M Madhavan, et al. (2001) Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol 14(5), 423-427.
124. C Parker, et al. (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85(12), 1958-1963.
125. PJ Kowalski, MA Rubin and CG Kleer (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5(6), R217-R222.
126. U Brinck, et al. (2004) Diffuse growth pattern affects E-cadherin expression in invasive breast cancer. Anticancer Res 24(4), 2237-2242.
127. RMM Moll, UH Frixen, et al. (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular carcinomas. Am J Pathol 143 1731-1742.
128. SA Rasbridge, CE Gillett, SA Sampson, et al. (1993) Epithelial (E) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol 169 245-250.
129. TL Mastracci, et al. (2005) E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 18 741-751.
130. Y Kanai, et al. (1994) Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res 85(10), 1035-1039.
131. JR Graff, et al. (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55(22), 5195-5199.
132. G Berx, et al. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13(9), 1919-1925.
133. T Nishizaki, et al. (1997) Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74(5), 513-517.
134. JE Etzell, et al. (2001) Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 32(3), 292-296.
135. S Droufakou, et al. (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 92(3), 404-408.
136. D Sarrio, et al. (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 106(2), 208-215.
137. CW Cheng, et al. (2001) Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20(29), 3814-3823.
138. D Sarrio, et al. (2004) Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23(19), 3272-3283.
139. NS Goldstein, LL Kestin and FA Vicini (2001) Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 92(4), 738-747.
140. WJ De Leeuw, et al. (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4), 404-411.
141. MA Gonzalez, et al. (1999) An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol 187(5), 523-529.
142. NS Goldstein (2002) Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am J Clin Pathol 118(3), 425-434.
143. TW Jacobs, et al. (2001) Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 25(2), 229-236.
144. NS Goldstein, et al. (2001) E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 115(4), 534-542.
145. H Lehr, A Folpe, H Yaziji, et al. (2000) Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114 190-196.
146. LP Middleton, et al. (2003) Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol 16(2), 120-129.
147. D O'Driscoll, et al. (2001) Lobular carcinoma in situ on core biopsy – what is the clinical significance? Clin Radiol 56(3), 216-220.
148. L Liberman, et al. (1999) Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol 173(2), 291-299.
149. SJ Shin and PP Rosen (2002) Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 126(6), 697-701.
150. AA Renshaw, et al. (2002) Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. Am J Clin Pathol 117(5), 797-799.
151. VP Bauer, et al. (2003) The management of lobular neoplasia identified on percutaneous core breast biopsy. Breast J 9(1), 4-9.
152. K Dmytrasz, et al. (2003) The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J 9(1), 10-12.
153. WA Berg, HE Mrose and OB Ioffe (2001) Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology 218(2), 503-509.
154. LE Philpotts, et al. (2000) Uncommon high-risk lesions of the breast diagnosed at stereotactic core-needle biopsy: clinical importance. Radiology 216(3), 831-837.
155. AH Lee, et al. (2003) Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology 42(4), 331-336.
156. RR Zhang (2001) Atypical lobular hyperplasia or lobular carcinoma in situ on large core needle biopsy of the breast: is surgical excision necessary? Am J Clin Pathol 116 610.
157. A Pacelli and KK Amrami (2001) Outcome of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed by core needle biopsy; clinical and surgical follow-up of 30 cases. Am J Clin Pathol 116 591A.
158. TM Elsheikh (2001) Is follow-up surgical excision indicated when breast core needle biopsies show lobular hyperplasia or lobular carcinoma in situ? A correlative study of 22 patients. Mod Pathol 14 25A.
159. B Clark and DJ Dabbs (2005) The quantitative significance of lobular neoplasia and atypical ductal hyperplasia in breast needle core biopsy. Mod Pathol 18(1), 30A.
160. A Sapino, et al. (2000) Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch 436(5), 421-430.
161. G Arpino, et al. (2004) Lobular neoplasia on core-needle biopsy – clinical significance. Cancer 101(2), 242-250.
162. TM Elsheikh and JF Silverman (2005) Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 29(4), 534-543.
163. DL Page, et al. (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361(9352), 125-129.
164. CB Vos, et al. (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 76(9), 1131-1133.
165. R Bassler and H Kronsbein (1980) Disseminated lobular carcinoma – a predominantly pleomorphic lobular carcinoma of the whole breast. Pathol Res Pract 166(4), 456-470.
166. N Weidner and JP Semple (1992) Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 23(10), 1167-1171.
167. V Eusebi, F Magalhaes, JG Azzopardi, et al. (1992) Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. Hum Pathol 23 655-662.
168. JS Bentz, N Yassa and F Clayton (1998) Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 11(9), 814-822.
169. JM Radhi (2000) Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology 36(2), 156-160.
170. LP Middleton, D Palacios, B Bryant, et al. (2000) Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24(12), 1650-1656.
171. D Frolik, R Caduff and Z Varga (2001) Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 39(5), 503-513.
172. N Sneige, et al. (2002) Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 15(10), 1044-1050.
173. J Palacios, et al. (2003) Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol 16(7), 674-678.
174. Y Chen, P Fitzgibbons, T Jacobs, et al. (2005) Pleomorphic apocrine lobular carcinoma in situ. Phenotypic and genetic study of a distinct variant of lobular carcinoma. Mod Pathol 18(1), 29A.
175. ER Fisher, et al. (1977) Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol 8(6), 679-683.
176. I Green, et al. (1997) A comparative study of pure tubular and tubulolobular carcinoma of the breast. Am J Surg Pathol 21(6), 653-657.
177. N Esposito, M Chivukula and DJ Dabbs (2001) Tubulolobular carcinoma: A morphologic and immunophenotypic study of 11 cases. Mod Pathol 18(1), 33A.
178. M Filotico, et al. (1983) Histiocytoid carcinoma of the breast. A problem of differential diagnosis for the pathologist. Report of a case. Pathologica 75(1037), 429-433.
179. D Gupta, et al. (2002) E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. Ann Diagn Pathol 6(3), 141-147.
180. B Lazzaro, et al. (2001) Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 9(3), 234-241.
181. M Feinmesser, et al. (2000) HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol 53(4), 286-291.
182. DEJ Haagensen, G Mazoujian, WDJ Holder, et al. (1977) Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg 185 279-285.
183. LC Murphy, M Lee-Wing, GJ Goldenberg, et al. (1987) Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo. Cancer Res 47 4160-4164.
184. L Losi, R Lorenzini, V Eusebi, et al. (1995) Apocrine differentiation in invasive carcinoma of the breast: Comparison of monoclonal and polyclonal gross cystic disease fluid protein-15 antibodies with prolactin-inducible protein mRNA expression. Appl Immunohistochem 3 91-98.
185. G Mazoujian, TH Parish, DEJ Haagensen, et al. (1988) Immunoperoxidase localization of GCDFP-15 with mouse monoclonal antibodies versus rabbit antiserum. J Histochem Cytochem 36 377-382.
186. MR Wick, TJ Lillemoe, GT Copland, et al. (1989) Gross cystic disease fluid protein-15 as a marker for breast cancer: Immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 20 281-287.
187. P Viacava, AG Naccarato and GS Bevilacqua (1998) Spectrum of GCDFP-15 expression in human fetal and adult normal tissues. Virchows Arch 432 255-260.
188. G Mazoujian and R Margolis (1988) Immunohistochemistry of gross cystic disease fluid protein (GCDFP-15) in 65 benign sweat gland tumors of the skin. Am J Dermatopathol 10 28-35.
189. G Mazoujian, GS Pinkus, S David, et al. (1983) Immunohistochemistry of a breast gross cystic disease fluid protein (GCDFP-15): A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 110 105-112.
190. PE Swanson, G Pettinato, TJ Lillemoe, et al. (1991) Gross cystic disease fluid protein-15 in salivary gland tumors. Arch Pathol Lab Med 115 158-163.
191. M Wick, DM Ockner, SE Mills, et al. (1998) Homologous carcinomas of the breasts, skin and salivary glands: A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma and salivary duct carcinoma. Am J Clin Pathol 109 75-84.
192. AH Ormsby, JL Snow, WPD Su, et al. (1995) Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: A statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. J Am Acad Dermatol 32 711-716.
193. G Mazoujian, C Bodian, DEJ Haagensen, et al. (1989) Expression of GCDFP-15 in breast carcinomas: Relationship to pathologic and clinical factors. Cancer 63 156-161.
194. O Kaufman, T Deidesheimer, M Muehlenberg, et al. (1996) Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common sites. Histopathology 29 233-240.
195. SS Raab, SC Berg, PE Swanson, et al. (1993) Adenocarcinoma in the lung in patients with breast cancer: A prospective analysis of the discriminatory value of immunohistology. Am J Clin Pathol 100 27-35.
196. MI Fiel, G Cernaianu, DE Burstein, et al. (1996) Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol 40 637-641.
197. D Pritchard, CW Todd and ML Egan (1978) Chemistry of carcinoembryonic antigen. Methods Cancer Res 14 55-85.
198. IH Benoy, et al. (2004) Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer 91(10), 1813-1820.
199. MA Watson, et al. (1999) Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 59(13), 3028-3031.
200. PN Span, et al. (2004) Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 22(4), 691-698.
201. MJ Nunez-Villar, et al. (2003) Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 5(3), R65-R70.
202. JH Han, et al. (2003) Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med 127(10), 1330-1334.
203. A Ciampa, et al. (2004) Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer 102(6), 368-372.
204. T Tot (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37(2), 175-181.
205. T Svenberg (1976) Carcinoembryonic antigen-like substances of human bile: Isolation and partial characterization. Int J Cancer 17 588-596.
206. G Nach-J Pusztaszeri (1972) Demonstration of a partial identity between CEA and a normal glycoprotein. Immunochemistry 9 1031-1033.
207. ZP Pavelic, L Pavelic, K Pavelic, et al. (1991) Utility of anti-carcinoembryonic antigen monoclonal antibodies for differentiating ovarian adenocarcinomas from gastrointestinal metastases to the ovary. Gynecol Oncol 40 112-117.
208. R Moll, A Lowe, J Laufer, et al. (1992) Cytokeratin 20 in human carcinomas: A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 140 427-447.
209. D Larsimont, L Lespagnard, M Degeyten, et al. (1994) Medullary carcinoma of the breast: A tumor lacking keratin 19. Histopathology 24 549-552.
210. P Dalal and S Shousha (1995) Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions. Mod Pathol 8 413-416.
211. ML Jensen, H Kiaer and F Melsen (1996) Medullary carcinoma versus poorly differentiated ductal carcinoma: An immunohistochemical study with keratin 19 and estrogen receptor staining. Histopathology 29 241-245.
212. CE Bacchi, RL Garcia and AM Gown (1997) Immunolocalization of estrogen and progesterone receptors in neuroendocrine tumors of the lung, skin, gastrointestinal and female genital tracts. Appl Immunohistochem 5 17-22.
213. FT Deamant, MT Pombo and H Battifora (1993) Estrogen receptor immunohistochemistry as a predictor of site of origin in metastatic breast cancer. Appl Immunohistochem 1 188-192.
214. SO Vargas, KO Leslie, PM Vacek, et al. (1998) Estrogen receptor related protein 29 in primary non-small cell carcinoma: Pathologic and prognostic correlations. Cancer 82 1495-1500.
215. CW Beattie, NW Hansen and PA Thomas (1985) Steroid receptors in human lung cancer. Cancer Res 45 4206-4214.
216. U Kaiser, J Hofmann, M Schilli, et al. (1996) Steroid hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 67 357-364.
217. JM Su, HK Shu, H Chang, et al. (1996) Expression of estrogen and progesterone receptors in non-small cell lung cancer: Immunohistochemical study. Anticancer Res 16 3803-3806.
218. PT Cagle, DR Mody and MR Schwartz (1990) Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 50 6632-6635.
219. C Genestie, B Zafrani and B Asselain (1998) Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res 18 571-576.
220. C Allred, JM Harvey, M Berado, et al. (1999) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 155-168.
221. PM Ravdin (1999) Should HER-2 status be routinely measured for all breast cancer patients? Semin Oncol 26 117-123.
222. S Paik, J Bryant, C Park, et al. (1998) ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor negative breast cancer. J Natl Cancer Inst 90 1361-1370.
223. HB Muss, AD Thor, DA Berry, et al. (1994) C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330 1260-1266.
224. S Masood (1992) Estrogen and progesterone receptors in cytology. Diagn Cytopathol 8 475-491.
225. S Masood, S Dee and JD Goldstein (1991) Immunocytochemical analysis of progesterone receptors in breast cancer. Am J Clin Pathol 96 59-63.
226. A Marrazzo, P Taormina, P Leonardi, et al. (1995) Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer: A prospective study. Anticancer Res 15 521-526.
227. AA Keshgegian, K Inverso and TS Kline (1988) Determination of estrogen receptor by monoclonal antireceptor antibody in aspiration biopsy cytology from breast carcinoma. Am J Clin Pathol 89 24-29.
228. V Keunen-Boumeester, TH Van der Kwast, HA Van Laarhoven, et al. (1989) Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol 134 733.
229. TW Jacobs, KP Sisiopikou, JE Prioleau, et al. (1998) Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol 11 259-264.
230. A Zidan, JS Christie Brown, D Peston, et al. (1997) Estrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 50 27-29.
231. F Puglisi, PF Scalone, M Bazzocchi, et al. (1998) Image guided core breast biopsy: A suitable method for preoperative biological characterization of small (pT1) breast carcinomas. Cancer Lett 133 223-229.
232. E Kaiserling (2004) [Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology]. Pathologe 25(5), 362-374.
233. HJ Kahn, D Bailey and A Marks (2002) Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15(4), 434-440.
234. AY Chu, et al. (2005) Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18(1), 105-110.
235. GT Beatson (1896) On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2 104-107.
236. W McGuire, P Carbone and E Vollmer (1975) Estrogen receptors in human breast cancer New York: Raven Press
237. JD Jacquemier, J Hassoun, M Torrente, et al. (1990) Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages – immunohistochemical study of 107 cases. Breast Cancer Res Treat 15 109-117.
238. A Reiner, G Reiner, J Spona, et al. (1988) Histopathologic characterization of human breast cancer in correlation with estrogen receptor status: A comparison of immunocytochemical and biochemical analysis. Cancer 64 1149-1154.
239. ML Lesser, PP Rosen, RT Seine, et al. (1981) Estrogen and progesterone receptors in breast carcinoma: Correlations with epidemiology and pathology. Cancer 48 299-309.
240. GM Clark and WL McGuire (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 20-25.
241. L Castagnetta, A Traina, G Carruba, et al. (1992) The prognosis of breast cancer patients in relation to the estrogen receptor status of both primary disease and involved nodes. Br J Cancer 66 167-170.
242. B Brdar, D Graf, R Padovan, et al. (1988) Estrogen and progesterone receptors as prognostic factors in breast cancer. Tumori 74 45-52.
243. JP Crowe, CA Hubay, OH Pearson, et al. (1982) Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2 171-176.
244. GM Clark, WL McGuire, CA Hubay, et al. (1983) Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 309 1343-1347.
245. MF Pichon, C Pallud, K Hacene, et al. (1992) Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer. Eur J Cancer 28 1676-1680.
246. A Shintaku and JW Said (1987) Detection of estrogen receptors in routinely processed formalin-fixed paraffin sections of breast carcinoma: Use of DNAase pretreatment to enhance sensitivity of the reaction. Am J Clin Pathol 87 161-167.
247. JM Esteban, H Battifora, Z Warsi, et al. (1991) Quantification of estrogen receptors on paraffin embedded tumors by image analysis. Mod Pathol 4 53-57.
248. C Cohen, ER Unger, D Sgoutas, et al. (1991) Automated immunohistochemical estrogen receptor in fixed embedded breast carcinoma. Am J Clin Pathol 95 335-339.
249. B Frigo, L Scopsi, M Faber, et al. (1993) Application of an estrogen receptor-immunocytochemical assay primary monoclonal antibody to paraffin-embedded human breast tumor tissue: Personal experience and review of the literature. Appl Immunohistochem 1 136-142.
250. H Battifora, P Mehta, C Ahn, et al. (1993) Estrogen receptor immunohistochemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1 39-45.
251. A Styliandu and CS Papadimitriou (1992) Immunohistochemical demonstration of estrogen receptors on routine paraffin sections of breast carcinomas: A comparison with frozen sections and an enzyme immunoassay. Oncology (Basel) 49 15-21.
252. RL Katz, S Patel, N Sneige, et al. (1990) Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 15 191-203.
253. PN Cowen, J Teasdale, P Jackson, et al. (1990) Estrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay. Histopathology 17 319-325.
254. L Cheng, SW Binder and YS Fu (1988) Methods in laboratory investigation: Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest 58 346-353.
255. DD Giri, VJM Dangerfield, R Lonsdale, et al. (1987) Immunohistology of estrogen receptor content of adjacent cryostat sections of breast carcinoma by radioligand binding and enzyme assay. J Clin Pathol 40 734-740.
256. P Jackson, J Teasdale, PN Cowen, et al. (1989) Development and validation of a sensitive immunohistochemical estrogen receptor assay for use on archival breast cancer tissue. Histochemistry 92 149-152.
257. DM Graham, L Jin and RV Lloyd (1991) Detection of estrogen receptor in paraffin-embedded sections of breast carcinoma by immunohistochemistry and in situ hybridization. Am J Surg Pathol 15 475-485.
258. A-Y Leong and J Milios (1993) Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave antigen retrieval. Appl Immunohistochem 1 282-288.
259. DL Kell, O Kamel and RV Rouse (1993) Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue: Correlation of clones ER1D5 and 1A6 with a cytosol based hormone receptor assay. Appl Immunohistochem 1 275-281.
260. G Cattoretti, S Pileri, C Parravicini, et al. (1993) Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171 83-98.
261. H Battifora (1994) Immunocytochemistry of hormone receptors in routinely processed tissue: The new gold standard [Editorial]. Appl Immunohistochem 2 143-145.
262. FA Mauri, S Veronese, B Frigo, et al. (1994) ER1D5 and H222 (ER-ICA) antibodies to human estrogen receptor protein in breast carcinomas: Results of a multicentric comparative study. Appl Immunohistochem 2 157-163.
263. ER DeSombre, SM Thorpe, C Rose, et al. (1986) Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 46 4256s-4264s.
264. LB Kinsel, E Szabo, GL Greene, et al. (1989) Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49 1052-1056.
265. LP Pertschuk, DS Kim, K Nayer, et al. (1990) Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: Histopathologic, demographic and biochemical correlations and relationship to endocrine response and survival. Cancer 66 1663-1670.
266. LP Pertschuk, KB Eisenberg, AC Carter, et al. (1985) Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Cancer 55 1513-1518.
267. WL McGuire and M DeLaGarza (1973) Improved sensitivity in the measurement of estrogen receptors in human breast cancer. J Clin Endocrinol Metab 37 986-989.
268. C Taylor (1996) Paraffin section immunocytochemistry for estrogen receptor: The time has come. Cancer 77 2419-2422.
269. L Pertschuk, J Feldman, K Eisenberg, et al. (1988) Immunohistochemical detection of progesterone receptor in breast cancer with monoclonal antibody: Relation to biochemical assay, disease-free survival, and clinical endocrine response. Cancer 62 342-349.
270. M Ferno, C Andersson, G Fallenius, et al. (1996) Estrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol 35 17-22.
271. W Remmele and KH Schicketanz (1993) Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: Computer-assisted image analysis. Pathol Res Pract 189 862-866.
272. D Schultz, RL Katz, S Patel, et al. (1992) Comparison of visual and CAS-200 quantitation of immunocytochemical staining in breast carcinoma samples. Anal Quant Cytol Histol 14 35-40.
273. DM Barnes, RR Millis, LVAM Beex, et al. (1998) Increased use of immunohistochemistry for estrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer 34 1677-1682.
274. GM Clark, JM Harvey, CK Osborne, et al. (1997) Estrogen receptor status determined by immunohistochemistry is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients. Proc Am Soc Clin Oncol 16 29A.
275. PJ van Diest, DR Weger, J Lindholm, et al. (1996) Reproducibility of subjective immunoscoring of steroid receptors in breast cancer. Anal Quant Cytol Histol 18 351-354.
276. DC Wilbur, J Willis, RA Mooney, et al. (1992) Estrogen and progesterone detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: A comparison in immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol 5 79-84.
277. M Tesch, A Shawwa and R Henderson (1993) Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol 99 8-12.
278. RA McClelland, P Finlay, KJ Walker, et al. (1990) Automated quantitation of immunohistochemical localized estrogen receptors in human breast cancer. Cancer Res 50 3545-3550.
279. JM Esteban, PI Kandalaft and P Mehta (1993) Improvement of the quantification of estrogen and progesterone receptors in paraffin-embedded tumors by image analysis. Am J Clin Pathol 99 32-38.
280. C Charpin, L Andrac, M-C Habib, et al. (1989) Immunodetection in fine-needle aspirates and multiparametric (SAMBA) image analysis: Receptors (monoclonal antiestrogen and antiprogesterone) and growth fraction (monoclonal Ki-67) evaluation in breast carcinomas. Cancer 63 863-872.
281. L Layfield, EA Saria, DH Conlon, et al. (1996) Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: Prognostic significance. J Surg Oncol 61 177-184.
282. I de Mascarel, G Soubeyran, J MacGrogan, et al. (1995) Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem 3 222-231.
283. LP Pertschuk, JG Feldman, YD Kim, et al. (1996) Estrogen receptor immunocytochemistry in paraffin-embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77 2514-2519.
284. SM Veronese, M Barbareschi and L Morelli (1995) Predictive value of ER1D5 antibody immunostaining in breast cancer: A paraffin-based retrospective study of 257 cases. Appl Immunohistochem 3 85-90.
285. DM Barnes, WH Harris, P Smith, et al. (1996) Immunohistochemical determination of estrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74 1445-1451.
286. H Goulding, S Pinder, P Cannon, et al. (1995) A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26 291-294.
287. JM Harvey, GM Clark, CK Osborne, et al. (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clinical Oncology 17(5), 1474-1481.
288. RM Elledge, et al. (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89(2), 111-117.
289. ER Fisher, et al. (2005) Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 103(1), 164-173.
290. SK Mohsin, et al. (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17(12), 1545-1554.
291. I Marcot, C Migeon, RM Parache, et al. (1997) A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry. Bull Cancer 84 613-618.
292. SO Tabbarra, MK Sidaway, A Frost, et al. (1998) The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer 84 355-360.
293. SW Leung and YC Bedard (1999) Estrogen and progesterone receptor contents in ThinPrep processed fine needle aspirates of breast. Am J Clin Pathol 112 50-56.
294. PP Rosen, CJ Menendez-Botet, JS Nisselbaum, et al. (1975) Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer 35 3187-3194.
295. M Nadji, et al. (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1), 21-27.
296. L Layfield, E Saria, EE Mooney, et al. (1998) Tissue heterogeneity of immunohistochemically detected estrogen receptor: Implications for image analysis quantification. Am J Clin Pathol 110 758-764.
297. G MacGrogan, I Soubeyran, I DeMascarel, et al. (1996) Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: A correlative study of 942 cases. Appl Immunohistochem 4 219-227.
298. EM Gibney, D Lawson, PB DeRose, et al. (1998) Image cytometric progesterone quantitation: Comparison with visual semiquantitation and cytosolic assay. Appl Immunohistochem 6 62-68.
299. JM Elias, M Margiotta, TR Sexton, et al. (1994) Immunohistochemical detection of sex steroid receptors in breast carcinoma using routine paraffin sections: Comparison with frozen sections and enzyme immunoassay. J Cell Biochem Suppl 19 126-133.
300. S Soomo, S Shousa and HD Sinnet (1992) Estrogen and progesterone receptors in screen-detected carcinoma: An immunohistological study using paraffin sections. Histopathology 21 543-547.
301. E Pennsi (1997) Differing roles found for estrogen's two receptors. Science 277 1439.
302. GGJM Kuiper, E Enmark, M Pelto-Huikko, et al. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93 5925-5930.
303. K Paech, P Webb, GGJM Kuiper, et al. (1997) Differential ligand activation of estrogen receptor alpha and ER beta at AP1 sites. Science 277 1508-1510.
304. Y Choi and M Pinto (2005) Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers. Appl Immunohistochem Mol Morphol 13(1), 19-24.
305. SA Fuqua, et al. (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10), 2434-2439.
306. D Stefanou, et al. (2004) Estrogen receptor beta (ERbeta) expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the Greek experience. Eur J Gynaecol Oncol 25(4), 457-461.
307. TA Hopp, et al. (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10(22), 7490-7499.
308. C Bargmann, MC Hung and RA Weinber (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319 226-230.
309. A Schecter, DF Stern, L Vaidyanathan, et al. (1984) The neu oncogene: An erb-B-related gene encoding an 185,000 Mr tumor antigen. Nature 312 513-516.
310. CR King, MH Kraus and SA Aaronson (1985) Amplification of a novel V-erbB-related gene in a human mammary carcinoma. Science 229 974-976.
311. NC Popescu, CR King and MH Kraus (1989) Location of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4 362-366.
312. C Shih, LC Padhy, M Murray, et al. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290 261-264.
313. DJ Slamon, GM Clark, SG Wong, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of Her-2/neu oncogene. Science 235 177-182.
314. W Hanna, HJ Kahn and M Trudeau (1999) Evaluation of Her-2/neu (erbB-2) status in breast cancer: From bench to bedside. Mod Pathol 12 827-834.
315. G Clark (1998) Should selection of adjuvant chemotherapy for patients with breast cancer be based on erb-2 status? J Natl Cancer Inst 90 1320-1321.
316. IL Andrulis, SB Bull, ME Blackstein, et al. (1998) Neu/erbB-2 amplification identifies a poor prognosis group of women with node-negative breast cancer. J Clin Oncol 16 1340-1349.
317. S Bianchi, M Paglierani, G Zampi, et al. (1993) Prognostic significance of cerbB-2 expression in node negative breast cancer. Br J Cancer 67 625-629.
318. A Borg, AK Tandon, H Sigurdsson, et al. (1990) HER-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 50 4332-4337.
319. GM Clark and WL McGuire (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51 944-948.
320. C Lovekin, IO Ellis, A Locker, et al. (1991) C-erb-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63 439-443.
321. AH McCann, PA Dervan, M O'Reagan, et al. (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51 3296-3303.
322. M Noguchi, N Koyasaki, N Ohta, et al. (1992) C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node positive breast cancer. Cancer 69 2953-2960.
323. SM O'Reilly, DM Barnes, RS Camplejohn, et al. (1991) The relationship between c-erbB-2 expression, S-phase fraction, and prognosis in breast cancer. Br J Cancer 63 444-446.
324. MC Paterson, KD Dietrich, J Kanylik, et al. (1991) Correlation between c-erbB-2 amplification and risk of recurrent disease in lymph node negative breast cancer. Cancer Res 54 556-567.
325. PP Rosen, ML Lesser, CD Arroyo, et al. (1995) Immunohistochemical detection of HER-2/neu in patients with axillary lymph node-negative breast carcinoma. Cancer 75 1320-1326.
326. S Toikkanen, H Helin, J Isola, et al. (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 20-year follow-up. J Clin Oncol 10 1044-1048.
327. MF Pres, G Hung, GW Godolphin, et al. (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 2771-2777.
328. R Anbazhagan, RD Gelber, R Bettelheim, et al. (1991) Association of c-erbB-2 expression and S phase fraction in the prognosis of node-positive breast cancer. Ann Oncol 2 47-53.
329. AL Borresen, L Ottestad, A Gaustad, et al. (1990) Amplification and protein overexpression of the neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: Relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 62 585-590.
330. BA Gusterson, RD Gelber, A Goldhirsch, et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10 1049-1056.
331. JR Marks, PA Humphrey, K Wu, et al. (1994) Overexpression of p53 and Her-2/neu proteins as prognostic markers in early-stage breast cancer. Ann Surg 219 332-341.
332. N Quenel, J Wafflart, F Bonichon, et al. (1995) The prognostic value of c-erbB-2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 35 283-291.
333. F Rilke, MI Colnaghi, N Cascinelli, et al. (1991) Prognostic significance of Her-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49 44-49.
334. J Winstanley, T Cooke, GD Murray, et al. (1991) The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63 447-450.
335. I Schonborn, W Zschiesche, E Spitzer, et al. (1994) C-erbB-2 overexpression in primary breast cancer: Independent prognostic factor in patients at high risk. Breast Cancer Res Treat 29 287-295.
336. B Tetu and J Brisson (1994) Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73 2359-2365.
337. OP Kallioniemmi, K Holli, T Visakorpi, et al. (1991) Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer. Int J Cancer 49 650-655.
338. D Slamon, B Leyland-Jones, S Shak, et al. (1998) Addition of Herceptin (humanized anti-Her-2 antibody) to first-line chemotherapy for (Her-2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc ASCO 17 98a.
339. MD Pegram, A Lipton, DF Hayes, et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 Her-2/neu monoclonal antibody plus cisplatin in patients with Her-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 2659-2671.
340. CL Vogel, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3), 719-726.
341. D Slamon, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344 783-792.
342. DL Persons, KA Borrelli and PH Hsu (1997) Quantitation of Her-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10 720-727.
343. A Mezzelani, L Alasio, C Bartoli, et al. (1999) C-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine needle aspirates. Br J Cancer 80 519-525.
344. C Lottner, et al. (2005) Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 205(5), 577-584.
345. G Pauletti, W Godolphin, M Press, et al. (1996) Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13 63-72.
346. S Paik, et al. (2002) Real world performance of HER2 testing-national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 94 852-854.
347. P Roche, et al. (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 855-857.
348. J Andersson, et al. (2004) HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescence in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1), 14-20.
349. S Wang, et al. (2001) Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116(4), 495-503.
350. MA Owens, BC Horten and MM Da Silva (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1), 63-69.
351. PC Roche and JN Ingle (1999) Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 17 434.
352. TW Jacobs, AM Gown, H Yazdii, et al. (2000) Her-2/neu protein expression in breast cancer evaluated by immunohistochemistry. Am J Clin Pathol 113 251-258.
353. MF Press, et al. (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20(14), 3095-3105.
354. A Rhodes, et al. (2004) The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol 122(1), 51-60.
355. RJ Zarbo and ME Hammond (2003) Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127(5), 549-553.
356. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126 803-808.
357. JS Ross, et al. (2003) HER-2/neu testing in breast cancer. Am J Clin Pathol 120(Suppl), S53-S71.
358. C Hauser-Kronberger and N Dandachi (2004) Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 35(6), 647-653.
359. CR Wixom, EA Albers and N Weidner (2004) Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 12(3), 248-251.
360. MA Madrid and RW Lo (2004) Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res 6(5), R593-R600.
361. L Arnould, et al. (2003) Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88(10), 1587-1591.
362. DJ Dabbs (1995) Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Mod Pathol 8(6), 637-642.
363. RI Nicholson, et al. (1993) Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A(7), 1018-1823.
364. RI Nicholson, et al. (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29(1), 117-125.
365. AK Sharma, et al. (1994) Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69(6), 1032-1037.
366. JG Klijn, et al. (1994) The prognostic value of epidermal growth factor receptor (EGFR) in primary breast cancer: results of a 10-year follow-up study. Breast Cancer Res Treat 29(1), 73-83.
367. EP Diamandis, H Yu and C Lopez-Otin (1996) Prostate specific antigen – a new constituent of breast fluid. Breast Cancer Res Treat 38 259-264.
368. DN Melegos and EP Diamandis (1996) Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. Clin Biochem 29 193-200.
369. H Yu, EP Diamandis and DJ Sutherland (1994) Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27 75-79.
370. H Yu, EP Diamandis, M Levesque, et al. (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40 171-178.
371. N Kidwai, et al. (2004) Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 6(1), R18-R23.
372. PJ Carder, et al. (2005) Expression of prostate specific antigen in male breast cancer. J Clin Pathol 58(1), 69-71.
373. RK Gupta (1999) Immunoreactivity of prostate specific antigen in male breast carcinomas: Two examples of a diagnostic pitfall in discriminating a primary breast cancer from metastatic prostate carcinoma. Diagn Cytopathol 21 167-169.
374. IK Komenaka, M El-Tamer, E Pile-Spellman, et al. (2003) Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch Surg 138(9), 987-990.
375. S Carvalho, et al. (2004) c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 57(10), 1075-1079.
376. GM Tse, et al. (2005) Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 58(2), 185-189.